ArticlePloS one2012
Breast cancer attributable costs in Germany: a top-down approach based on sickness funds data.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The global impact of non-communicable diseases on healthcare spending and national income: a systematic review.European journal of epidemiology · 2015Pooled it
- A cost-effectiveness analysis of breast cancer treatment in certified versus non-certified hospitals in Germany.International journal of cancer · 2026Article
- Estimation of the stage-wise costs of breast cancer in Germany using a modeling approach.Frontiers in public health · 2022Review
- Cost-effectiveness of MR-mammography as a solitary imaging technique in women with dense breasts: an economic evaluation of the prospective TK-Study.European radiology · 2021Article
- Healthcare costs associated with breast cancer in Germany: a claims data analysis.The European journal of health economics : HEPAC : health economics in prevention and care · 2020Article
- Determining Breast Cancer Treatment Costs Using the Top Down Cost Approach.European journal of breast health · 2019Article
- Observational
- Estimating Costs of Care Attributable to Cancer: Does the Choice of Comparison Group Matter?Health services research · 2018Article
- Productivity losses and public finance burden attributable to breast cancer in Poland, 2010-2014.BMC cancer · 2017Article
- Cost-of-illness studies based on massive data: a prevalence-based, top-down regression approach.The European journal of health economics : HEPAC : health economics in prevention and care · 2016Article
- The association between health system development and the burden of cardiovascular disease: an analysis of WHO country profiles.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer is the leading cause of death from cancer among women in Germany. Despite its clinical and economic relevance, no attributable costs for breast cancer have been reported for Germany so far. The objective of this study is to estimate age-specific breast cancer attributable health expenditures for Germany.
methodsSickness fund data from 1999 representing about 26 million insured (i.e. 32% of the total German population) have been analysed using generalized additive models and the error propagation law. Costs have been inflated to 2010.
resultsBreast cancer attributable costs decreased with age. Among breast cancer patients aged 30-45 years, about 90% of all health expenditures were due to breast cancer, whereas in breast cancer patients aged 80-90 years, about 50% were due to breast cancer. Breast cancer attributable costs amounted to about €9,000 annually for patients below 55 years of age and declined to about €3,000 in 90-year-old breast cancer patients.
conclusionThis analysis provides estimates of attributable breast cancer costs in Germany. Compared with the international literature, the estimates were plausible but had a tendency to underestimate breast cancer attributable costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.